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Abstract
Background: Wilson’s disease (WD) is an autosomal recessive disorder of copper metabolism resulting in
multifaceted neurological, hepatic, and psychiatric symptoms. The objective of the study was to comparatively
assess two clinical rating scales for WD, the Unified Wilson’s Disease Rating Scale (UWDRS) and the Global
Assessment Scale for Wilson’s disease (GAS for WD), and to test the feasibility of the patient reported part of the
UWDRS neurological subscale (termed the “minimal UWDRS”).
Methods: In this prospective, monocentric, cross-sectional study, 65 patients (median age 35 [range: 15–62] years;
33 female, 32 male) with treated WD were scored according to the two rating scales.
Results: The UWDRS neurological subscore correlated with the GAS for WD Tier 2 score (r = 0.80; p < 0.001).
Correlations of the UWDRS hepatic subscore and the GAS for WD Tier 1 score with both the Model for End Stage
Liver Disease (MELD) score (r = 0.44/r = 0.28; p < 0.001/p = 0.027) and the Child-Pugh score (r = 0.32/r = 0.12; p = 0.
015/p = 0.376) were weak. The “minimal UWDRS” score significantly correlated with the UWDRS total score (r = 0.
86), the UWDRS neurological subscore (r = 0.89), and the GAS for WD Tier 2 score (r = 0.86).
Conclusions: The UWDRS neurological and psychiatric subscales and the GAS for WD Tier 2 score are valuable
tools for the clinical assessment of WD patients. The “minimal UWDRS” is a practical prescreening tool outside
scientific trials.
Keywords: Copper metabolism, German network of hereditary movement disorders (GeNeMove), Global
assessment scale for Wilson’s disease (GAS for WD), Unified Wilson’s disease rating scale (UWDRS), Wilson disease
Background
Wilson’s disease (WD) is an autosomal recessive dis-
order caused by mutations in the ATP7B gene leading to
excessive copper overload, predominantly in the liver
and the brain [1, 2]. The severity of the disease varies
considerably between patients, and it remains unclear
why some patients have hepatic symptoms while others
develop neurological, psychiatric, or combined symp-
tomatology [3–5]. Hepatic features range from asymp-
tomatic patients with slightly elevated liver enzymes to
liver cirrhosis or acute hepatic failure [6]. Neurological
symptoms are usually characterized by multiple motor
impairments characteristic for dysfunctions of the basal
ganglia and the cerebellum. This results in various
neurological symptoms including rigidity, tremor, dys-
kinesia, dystonia, ataxia, chorea, dysarthria, dysphagia,
or excessive salivation [6–10]. Psychiatric symptoms are
diverse and may include concentration difficulties, atten-
tion disorders, behavioral abnormalities with alterations
of personality, depression, and psychosis [11–14]. The
severity of the symptoms clearly determines the extent
to which a patient is restricted in their activities of daily
living (ADL).
To prevent progression of the disease and lethal out-
comes, lifelong therapy pursuing a negative copper bal-
ance is imperative; hence, underlining the importance of
an early diagnosis and an individually adapted therapy
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[15]. However, neurological worsening in WD patients
following initiation of penicillamine standard therapy is
a major concern [16]. Given the multifaceted symp-
tomatology in WD, a comprehensive, standardized, and
practical clinical rating scale is indispensable to monitor
individual therapeutic effects and side effects in daily
practice and to use as a valid end point in clinical trials
testing therapies.
Currently, there are two clinical rating scales for WD:
the Unified Wilson’s Disease Rating Scale (UWDRS) and
the Global Assessment Scale for Wilson’s Disease (GAS
for WD). The UWDRS has neurological, hepatic, and
psychiatric subscales. The neurological subscale of the
UWDRS was developed in collaboration with the Euro-
pean Network, EuroWilson, and the German Network
of Hereditary Movement Disorders (GeNeMove). The
first WD rating scale reflecting the extent of neuro-
logical impairment was reported by Czlonkowska et al.
in 2007 [17]. It was extended by hepatic and psychiatric
subscales that were evaluated in total by Leinweber et al.
in 2008 [18]. The GAS for WD, considerably shorter
than the UWDRS, is comprised of two tiers scoring
global disability (Tier 1) and neurological dysfunction
(Tier 2) and was proposed by Aggarwal et al. in 2009
[19]. Potential difficulties that have arisen from both
rating scales in daily practice are the relatively long dur-
ation of the complete clinical assessment and the formal
requirement of two to three different medical specialists
(i.e., neurology, gastroenterology, and psychiatry).
So far the UWDRS and the GAS for WD have not
been directly compared, and it remains unclear which
rating scale may be superior. Hence, the goal of the
present study is to evaluate the UWDRS and the
GAS for WD in routine clinical practice and to
propose a less time consuming patient reported pre-
screening tool for use outside scientific trials, the
“minimal UWDRS”.
Methods
Patients
This prospective, monocentric, cross-sectional study was
carried out between 2014 and 2015. The ethics committee
at the University of Heidelberg (Heidelberg, Germany) ap-
proved the study. A total of 65 patients with treated WD
were evaluated according to the UWDRS and the GAS for
WD. Patients older than 14 years of age who had been
diagnosed with WD according to the diagnostic and
phenotypic classification of WD [2] by the Department of
Gastroenterology at Heidelberg University Hospital were
enrolled after giving written informed consent. For pa-
tients who were under 18 years of age, written informed
consent was obtained from the parents or the legal guard-
ians. Patient related information including gender, age at
assessment, age at the time of diagnosis, initial mode of
manifestation, treatment at assessment, and clinical pa-
rameters were collected.
Clinical evaluation of the UWDRS and the GAS for WD
The full UWDRS (maximum score 320 points) consists
of three subscales representing three main features of
clinical manifestation in WD: a neurological subscale (27
items, 208 points), a hepatic subscale (9 items, 36
points), and a psychiatric subscale (19 items, 76 points).
Of the 55 items in total, the patient has to answer 26
questions, whereas 29 items need to be scored by the
observer. Each item is scored on an ascending five point
scale (0 points “no symptoms” and 4 points “worst char-
acteristic possible”) [17, 18].
The GAS for WD contains two parts. Tier 1 scores
global disability in four areas: liver, cognition and behav-
ior, motor, and osseomuscular (with an ascending six
point scale (0–5); the scores of each item are not
summed up). Tier 2 scores neurological dysfunction and
consists of 14 items with an ascending five point scale
(0–4). The items of Tier 2 are summed for a possible
maximum of 56 points [19]. All clinical assessments
were performed by a resident in internal medicine (H.
M. Volpert) supervised by both an attending hepatolo-
gist (K. H. Weiss) and an attending neurologist (M.
Weiler). Disagreements between the investigators were
resolved by discussion.
The “minimal UWDRS”
The first nine items of the UWDRS neurological sub-
scale were selected to develop a minimal neurological
subscale, newly determined as the “minimal UWDRS.”
Since this reduced rating scale exclusively represented a
questionnaire whose items are reported by the patient or
their family (usually referring to the previous two to four
weeks), the resulting score can be assessed before the
consultation with the treating physician. The selected
items are: item 1 “mobility”, item 2 “falling”, item 3 “sali-
vation”, item 4 “swallowing”, item 5 “feeding”, item 6
“dressing”, item 7 “taking a bath or shower”, item 8
“grooming”, and item 9 “toilet use”. Apart from items 3
and 4, all other questions assess the level of independ-
ence for ADL.
Statistical analysis
Comparison of the UWDRS with the GAS for WD
UWDRS and GAS for WD were compared by correlat-
ing the scores of the rating scales and subscales in scat-
ter diagrams and by calculating the Pearson’s correlation
coefficient. Correlation coefficients were interpreted as
weak (r < 0.5), moderate (r = 0.5–0.79), and strong
(r ≥ 0.80) [20]. To validate the UWDRS hepatic subscore
and the GAS for WD Tier 1 “liver” domain, these
items were each correlated with the Model for End
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Stage Liver Disease (MELD) score and the Child-Pugh
score [21, 22]. The frequencies of scoring 1, 2, 3, or 4 points
were calculated as well as the percentage of scoring >0
points for each item. Internal consistencies were evaluated
using Cronbach’s alpha (values of ≥0.7 were interpreted as
“good”, and ≥0.9 were interpreted as “very good”) [18].
Cronbach’s alpha was used to compare our results with the
results of previous studies that evaluated the two clinical
rating scales [18, 19]. In addition, single item total score
correlations were assessed.
Evaluation of the “minimal UWDRS”
The score of the newly developed “minimal UWDRS”
was correlated with the scores of the UWDRS and the
GAS for WD including their neurological subscores.
A p value <0.05 was considered statistically signifi-
cant. For statistical analysis, SPSS™ (version 20.0, IBM
Germany, Ehningen) was used.
Results
Descriptive analysis
Table 1 gives an overview of the clinical characteristics
of the 65 WD patients examined. Patients that presented
with hepatic symptoms as the initial mode of manifest-
ation totalled 70.8%. Table 2 shows the results of the
UWDRS and the GAS for WD both in general and in
dependence from the initial mode of manifestation (i.e.,
hepatic, neurological, combined hepatic/neurological,
and asymptomatic). As indicated by the relatively low
medians, patients with severe WD symptoms were rare
throughout the entire study. When patients were assessed
depending on their initial mode of manifestation, the
UWDRS total score and the UWDRS neurological sub-
score differed significantly (p values 0.026 and 0.012, re-
spectively), which reflected the neurological disease
burden in this subgroup. Additional file 1: Table S1 shows
significantly differing results of the UWDRS and the GAS
for WD when comparing clinical subgroups with respect
to gender, Kayser-Fleischer rings (KFR) at assessment, and
liver cirrhosis at the time of diagnosis. The prevalence of
subscores of each item including the respective single item
total score correlations are listed in the supporting data
(Additional file 1: Figure S1).
Correlations of the UWDRS, GAS for WD, and “minimal
UWDRS”
The correlation of the UWDRS total score with the
UWDRS neurological subscore is shown in Fig. 1a (cor-
relation coefficient of r = 0.96; level of significance of r:
p < 0.001). The UWDRS total score correlated with the
UWDRS hepatic subscore to a lower extent (correlation
coefficient of r = 0.37; level of significance of r:
p = 0.003; Fig. 1b) than the UWDRS total score with the
UWDRS psychiatric subscore (correlation coefficient of
r = 0.83; level of significance of r: p < 0.001; Fig. 1c).
Moreover, the UWDRS neurological subscore corre-
lated with the GAS for WD Tier 2 score (correlation
coefficient of r = 0.80; level of significance of r:
p < 0.001; Fig. 1d).
Figure 2 depicts the correlations of the UWDRS hep-
atic subscore and the score of the GAS for WD Tier 1
“liver” domain, respectively, with each the MELD and
the Child-Pugh score. The UWDRS hepatic subscore
correlated weakly with both the MELD score (correl-
ation coefficient of r = 0.44; level of significance of r:
p < 0.001; Fig. 2a) and the Child-Pugh score (correlation
coefficient of r = 0.32; level of significance of r:
p = 0.015; Fig. 2b). For the score of the GAS for WD
Tier 1 “liver” domain, results were similar: correlations
with each the MELD score (correlation coefficient of
r = 0.28; level of significance of r: p = 0.027; Fig. 2c) and
the Child-Pugh score (correlation coefficient of r = 0.12;
level of significance of r: p = 0.376; Fig. 2d) were weak.
The “minimal UWDRS” score significantly correlated
with each the UWDRS total score (r = 0.86; Fig. 3a), the
UWDRS neurological subscore (r = 0.89; Fig. 3b), and
the GAS for WD Tier 2 score (r = 0.86; Fig. 3c).
Single item total score correlation and Cronbach’s alpha
Single item total score correlations are listed in the sup-
porting data (Additional file 1: Figure S1, right). Cron-
bach’s alpha for the total UWDRS was 0.95, for the
UWDRS neurological subscale it was 0.96, for the
UWDRS hepatic subscale it was 0.65, and for the psychi-
atric subscale it was 0.83. No item could be deleted in
order to improve Cronbach’s alpha for the UWDRS
neurological subscale. After omitting item 30 “fecal
blood”, Cronbach’s alpha for the UWDRS hepatic subscale
changed to 0.66. The three items 39a “sexual interest in-
creased”, 50 “voice/noise level”, and 52b “mood depressed”
were left out to improve the internal consistency of the
UWDRS psychiatric subscale to 0.84. The internal
consistency of the GAS for WD Tier 2 score (Cronbach’s
alpha of 0.82) was slightly lower than the one for the
UWDRS neurological subscale. After omitting item 13
“KFR”, Cronbach’s alpha improved to 0.84.
Discussion
In the clinical management of WD, thorough clinical
monitoring including early detection of potential med-
ical side effects and therapy failure is crucial to improve
the patient’s motivation and adherence [23]. Therefore,
liver function tests and the calculation of MELD and
Child-Pugh scores on an every three months basis are
recommended [6, 21, 24]. During the initial phase of
treatment, the modified Nazer score is a reliable tool to
identify patients at risk for hepatic treatment failure re-
quiring liver transplantation [25, 26].
Volpert et al. BMC Neurology  (2017) 17:140 Page 3 of 9
Additionally, ultrasound of the liver visualizes the
status of cirrhotic reorganization. However, an adequate
assessment of neurological impairment has long been
neglected due to the lack of a suitable tool for evalu-
ation. Standardized neurological assessment allows for
both intra- and inter-individual comparison of symp-
toms, which improves follow up and adds the ability of
quantifying the severity of neurological symptoms. Espe-
cially for clinical trials on effects and side effects of
medical treatments in WD, neurological rating scales
are invaluable [27, 28]. This study presents the first
systematic comparison of two clinical rating scales
previously developed for WD, the UWDRS and the GAS
for WD, and evaluates their feasibility in routine clinical
practice. Additionally, we introduce the patient reported
part of the UWDRS neurological subscale, the “minimal
UWDRS”, as a handy and time saving prescreening tool
for the assessment of WD patients in routine clinical prac-
tice outside scientific trials.
The significant differences in the UWDRS total score
and the UWDRS neurological subscore observed in our
study show that the results differ depending on the
Table 1 Clinical characteristics of the 65 examined patients with WD
N Percentage Median Range
Gender
Female 33 50.8
Male 32 49.2
Age at assessment (yr)
All 35 15–62
Female 40 15–62
Male 29.5 16–62
Age at onset of symptoms (yr) 16 1–47
Age at time of diagnosis (yr) 17 3–54
Initial mode of manifestation
Hepatic 46 70.8
Hepatic + neurological 10 15.4
Neurological 6 9.2
Asymptomatic 3 4.6
Liver cirrhosis at time of diagnosis 21 32.3
By initial mode of manifestation
Hepatic [n = 46] 15 32.6
Hepatic + neurological [n = 10] 6 60.0
Liver status at assessment
MELD score [missing data n = 4] 7.3 6–17
Child-Pugh score [missing data n = 7] 5 5–11
KFR at time of diagnosis [missing data n = 8] 28 49.1
KFR at assessment 19 29.2
Treatment at assessment in all patients (n = 65)
D-Penicillamine 38 58.5
Trientine 16 24.6
Zinc 7 10.8
D-Penicillamine + zinc 2 3.1
Trientine + zinc 2 3.1
Treatment at assessment in neurologically symptomatic patients (n = 16)
Chelating agents 13 81.2
Zinc with or without chelating agent 3 18.8
Duration of treatment (yr) 15 0.4–47
Abbreviations: KFR Kayser-Fleischer ring, pts. patients, yr. years
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initial mode of manifestation (Table 2). The strong cor-
relation of the UWDRS total score with the UWDRS
neurological subscore (Fig. 1a) demonstrates that the
UWDRS neurological subscale represents the UWDRS
total scale very well. As the UWDRS neurological sub-
score can total 208 points at maximum, or 65% of the
total score, one reason for the strong correlation is that
the UWDRS neurological subscore largely represents the
UWDRS total score. In contrast, the correlation of the
UWDRS total score with the UWDRS hepatic subscore
is weak (Fig. 1b). Hence, the UWDRS hepatic scale does
not reflect chronic compensated liver disease, which is
common in WD [6]. The moderate correlation of the
UWDRS total score with the UWDRS psychiatric score
(Fig. 1c) reveals that patients with severe neurological or
hepatic symptoms do not necessarily have pronounced
concomitant psychiatric symptoms [14, 29]. More than
20% of the patients in the study were found to have fail-
ing memory (item 40), concentration difficulties (item
41), and reduced social contact (item 42), all being
Table 2 Overview of the UWDRS and GAS for WD Tier 2 (sub)scores
Total score median (range) P value
UWDRS total score 10 (0–97)
UWDRS neurological subscore 5 (0–74)
UWDRS hepatic subscore 2 (0–13)
UWDRS psychiatric subscore 1 (0–26)
GAS for WD Tier 2 score 3 (0–24)
Initial mode of manifestation
Hepatic Hepatic + neurological Neurological Asymptomatic
UWDRS total score 9 (0–55) 32.5 (2–97) 18.5 (5–76) 4 (3–5) 0.026*
UWDRS neurological subscore 6 (0–49) 21.5 (1–66) 14 (3–74) 4 (2–4) 0.012*
UWDRS hepatic subscore 2 (0–13) 2.5 (0–12) 1 (0–5) 1 (0–1) 0.546
UWDRS psychiatric subscore 1 (0–12) 1.5 (0–26) 2 (2–7) 0 (0–0) 0.081
GAS for WD Tier 2 score 2 (0–24) 5 (0–23) 4.5 (1–11) 2 (1–3) 0.099
*, P value statistically significant
Fig. 1 a Correlation of the UWDRS total score with the UWDRS neurological subscore. b Correlation of the UWDRS total score with the UWDRS
hepatic subscore. c Correlation of the UWDRS total score with the UWDRS psychiatric subscore. d Correlation of the UWDRS neurological
subscore with the GAS for WD Tier 2 score
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Fig. 2 a Correlation of the MELD score with the UWDRS hepatic subscore. b Correlation of the Child-Pugh score with the UWDRS hepatic sub-
score. c Correlation of the MELD score with the GAS for WD Tier 1 “liver” domain. d Correlation of the Child-Pugh score with the GAS for WD Tier
1 “liver” domain
Fig. 3 a Correlation of the UWDRS total score with the UWDRS minimal neurological (“minimal UWDRS”) subscore. b Correlation of the UWDRS
neurological subscore with the UWDRS minimal neurological (“minimal UWDRS”) subscore. c Correlation of the GAS for WD Tier 2 score with the
UWDRS minimal neurological (“minimal UWDRS”) subscore
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psychiatric disabilities frequently seen in patients with
WD [8, 30, 31]. A brief global psychiatric assessment as
provided by the UWDRS psychiatric subscale is doubt-
lessly inappropriate to reflect such disorders. Neverthe-
less, it can be supportive in identifying patients with
WD who would benefit from referral to a psychiatrist
for further exploration.
The UWDRS neurological subscore correlates strongly
with the GAS for WD Tier 2 score (Fig. 1d). Since the
UWDRS scale includes a larger number of neurology
and psychiatry related items than the GAS for WD scale,
it documents these disabilities in greater detail (with the
caveat that GAS for WD includes Kayser-Fleischer rings
as a feature, while the UWDRS does not). However, this
comes at some cost. In routine clinical practice, the lar-
ger number of items in the neurological and psychiatric
subscales of the UWDRS requires significantly more
time to assess than the Tier 2 score of the GAS for WD.
However, this may not be a concern in clinical trials,
particularly in those that assess therapeutic effects when
detailed documentation of a change in a single neuro-
logical symptom is inevitable [32]. More significantly,
many of the detailed neurological signs in the UWDRS
scale are difficult to reliably discern in practice, as is
reflected in the low interrater reliability (i.e., small values
for intraclass correlation coefficients [ICC] for some of
the individual items of the scale) [18]. In contrast, all the
individual items of the GAS for WD have ICC values in
the high range (i.e., can be assessed reliably) [19].
Whether a larger number of detailed items or a smaller
number of reliably assessable items are of greater benefit
will depend on the goal and the design of the individual
clinical trial, as well as the consistency in raters. For in-
stance, a trial interested in a specific neurological feature
(e.g., autonomic disturbances) that is included only in
the UWDRS is probably preferable. Likewise, the GAS
for WD may be more suitable for a longitudinal trial with
the goal of assessing a change in item scores in individual
patients over a long period of time involving many differ-
ent raters, as it reduces rater induced variance.
The weak correlation of the UWDRS hepatic subscore
with the MELD score (Fig. 2a) and the Child-Pugh score
(Fig. 2b) demonstrates that the UWDRS hepatic sub-
score does not mirror the current liver status very well.
The correlation of the GAS for WD Tier 1 “liver” do-
main with the MELD score (Fig. 2c) and the Child-Pugh
score (Fig. 2d) is also weak (i.e., this item does not repre-
sent the liver status very well either). Furthermore, we
could not reproduce the correlation coefficient of
r = 0.65 with respect to the Tier 1 “liver” domain and
the Child-Pugh score published by Aggarwal et al. in
2009 (in our study: r = 0.12). However as the Child-
Pugh score, as well as the MELD score to a lower extent,
might have a limitation in detecting significant changes
of the hepatic function in clinically stable or non-
cirrhotic liver patients, the most meaningful mode of
evaluation for the hepatic system in a WD specific rating
scale has yet to be established.
The “minimal UWDRS” score correlates strongly with
the UWDRS total score (Fig. 3a), the UWDRS neuro-
logical subscore (Fig. 3b), and the GAS for WD Tier 2
score (Fig. 3c). Outside clinical trials, the “minimal
UWDRS” is a convenient and time saving prescreening
tool to document neurological impairments in WD pa-
tients. The neurological questionnaire can be handed to
the patient in the waiting area before the medical ap-
pointment without the requirement of a neurologist.
Consequently, the questionnaire will help to better
structure the consultation as the patient would have
already deliberated his actual complaints and would be
more prepared for the physician’s questions. Besides, a
short questionnaire, likely to be applied more frequently
than an extensive neurological assessment, will support
self reflection on disease symptoms and thus improve
coping strategies as well as adherence to the treatment.
Furthermore, the use of a questionnaire is more eco-
nomical (after an initial detailed assessment), since it can
be applied to figure out which impairments should be
focused on and reevaluated at future follow up examina-
tions. As seven out of nine items in the “minimal
UWDRS” score the level of independence in the ADL,
the physician will learn rapidly whether the neurological
symptoms limit the patient’s ADL. Constrictively, the
questionnaire does not interrogate the exact reasons
underlying potential impairments of the ADL. A further
limitation is the “minimal UWDRS” may not adequately
capture the full breadth of neurological disability in pa-
tients with WD. For instance, the “minimal UWDRS”
may miss mild limb dystonia or new onset Kayser-
Fleischer rings, which can be early signs of noncompli-
ance or inadequate treatment. Thus, the time saving will
come at some cost to patient care.
Altogether, our study collective suffered from relatively
mild to moderate WD symptoms (Table 2, Additional
file 1: Figure S1). Hence, we can not use a single item
total score correlation to select single items for a min-
imal neurological scale. Otherwise, a minimal neuro-
logical scale will be inappropriate to be applied for
patients with severe WD symptoms. Internal consisten-
cies of the UWDRS total score and its subscales, as well
as the internal consistency of the GAS for WD neuro-
logical assessment, are all very similar to those reported
by Leinweber et al. 2008 and Aggarwal et al. 2009 [18,
19]. In our study, Cronbach’s alpha for the UWDRS total
score is 0.95 compared with 0.92 reported by Leinweber
et al., the UWDRS neurological subscale is 0.95 compared
with 0.94, the UWDRS hepatic subscale is 0.65 compared
with 0.59, and the UWDRS psychiatric subscale is 0.83
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compared with 0.76 [18]. Cronbach’s alpha for the GAS
for WD Tier 2 in our study (0.82) and in the first report
(0.89) is also similar [19]. In summary, we largely confirm
the internal consistencies for both the UWDRS and the
GAS for WD as reported by the previous two articles.
The high prevalence of the hepatic initial mode of
manifestation (70.8% in this study vs. an average of 45%
in the literature) observed in our study collective may be
due to selection bias caused by the fact that all patients
were recruited in a WD outpatient clinic in a Depart-
ment of Gastroenterology. The low median MELD (7.3)
and Child-Pugh (5) scores show that most patients suf-
fered from compensated liver cirrhosis. In general, our
study collective is only mildly to moderately affected,
which is probably due to the median duration of treat-
ment at study inclusion being 15 years (Table 1). Despite
the relatively long median time of pretreatment, patients
still were clinically impaired. This finding underlines the
importance of future studies focusing on improvement
of the medication utilized to treat WD.
Conclusions
The main conclusions of our study are the following:
i) The UWDRS neurological and psychiatric subscales
are valuable tools for a detailed assessment of
neurological and psychiatric impairment in patients
with WD.
ii) The GAS for WD Tier 2 can be considered as an
alternative to gain an overview of the extent of
neurological impairment.
iii)The UWDRS hepatic subscale, similar to the GAS
for WD Tier 1, shows weak correlation to
established hepatologic scores like MELD or Child-
Pugh. This finding underlines the need for further
assessment of liver specific rating scales in WD.
iv)We propose the patient reported “minimal UWDRS”
(a nine item questionnaire) is a feasible, economical
prescreening tool for the evaluation of the
neurological status in WD patients with mild to
moderate neurological symptoms.
v) Future studies are required to further evaluate the
UWDRS, the GAS for WD, and the “minimal
UWDRS” in WD patients with severe clinical
symptoms.
Additional file
Additional file 1: Figure S1. Prevalences of the single item scores.
Table S1. UWDRS and GAS for WD Tier 2 (sub)scores depending on
gender, KFR, and liver cirrhosis. (DOCX 506 kb)
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